<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment with rituximab or obinutuzumab produces a marked decrease of B-lymphocytes that may persist for a long time after treatment discontinuation.
 <sup>
  <xref rid="R94" ref-type="bibr">94</xref>
 </sup> Rituximab therapy may facilitate JC and hepatitis B viral reactivation.
 <sup>
  <xref rid="R95" ref-type="bibr">95</xref>,
  <xref rid="R96" ref-type="bibr">96</xref>
 </sup> Humoral immunity appears to facilitate COVID-19 recovery.
 <sup>
  <xref rid="R97" ref-type="bibr">97</xref>
 </sup>
</p>
